A Phase I/II, Multi-Center, Open-Label Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer.

Trial Profile

A Phase I/II, Multi-Center, Open-Label Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2015

At a glance

  • Drugs BGT 226 (Primary)
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 13 Oct 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 13 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top